<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Esco Aster Pte. Ltd. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=49777></link><description><![CDATA[Esco Aster Pte. Ltd. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Tue, 05 May 2026 02:46:50 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2025/12/12_1028147215_20251218142940_1336587304.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1025649</link><description><![CDATA[SINGAPORE--(Business Wire/Korea Newswire)--Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The ...]]></description><pubDate>Thu, 18 Dec 2025 15:00:00 +0900</pubDate></item><item><title><![CDATA[에스코 애스터, 샤인온 바이오메디컬과 혁신적인 계열 내 최초 HLA-G 표적 엑소좀 약물 전달 플랫폼 위한 임상 cGMP 생산 계약 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1025650</link><description><![CDATA[싱가포르--(Business Wire/뉴스와이어)--싱가포르 JTC 런치패드(JTC LaunchPad Singapore)에 소재한 수직 통합 세포 및 유래물 위탁연구개발생산기관(CRDMO)인 에스코 애스터(Esco Aster)가 샤인온 바이오메디컬(Shine-On Biomedical)의 HLA-G 표적 엑소좀 프로그램에 대한 화학·제조·품질관리(CMC) 생산을 지원한다고 밝혔다. 샤인온 바이오메디컬은 에스코 애스터의 세포주 플랫폼을 활용한 고수율 엑소좀 개발을...]]></description><pubDate>Thu, 18 Dec 2025 15:00:00 +0900</pubDate></item></channel></rss>